×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
FDA declines to approve Satsuma's migraine treatment STS101
Pharmaceutical Technology
The US FDA has declined to grant approval for Satsuma Pharmaceuticals' STS101 for acute migraine treatment in adults.
3 months ago
US FDA declines to approve Shin Nippon Biomedical's migraine drug
Reuters
The U.S. health regulator has declined to approve Japan-based Shin Nippon Biomedical Laboratories' treatment for acute migraine late on...
3 months ago
FDA turns down Satsuma's nasal migraine treatment
Pharmaphorum
Manufacturing problems have scuppered Satsuma Pharma's chances of a timely FDA approval for its intranasal migraine therapy STS101.
3 months ago
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational ...
GlobeNewswire
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial...
11 months ago
Shin Nippon Biomedical Laboratories acquires Satsuma Pharmaceuticals
The Business Journals
A pharmaceutical company in Durham thats running low on cash is going private by returning to its roots.
10 months ago
SNBL agrees to buy Satsuma Pharmaceuticals
Pharmaceutical Technology
SNBL has signed a definitive agreement to acquire US-based development-stage biopharmaceutical firm Satsuma Pharmaceuticals.
12 months ago
Satsuma in the red after migraine candidate fails phase 3 again
Fierce Biotech
New device, new trial, same flop. That is the story at Satsuma Pharmaceuticals, which suffered a second stock-crushing phase 3 belly-flop...
17 months ago
SNBL to Acquire Satsuma Pharmaceuticals
GlobeNewswire
Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront...
12 months ago
Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors
PR Newswire
PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell...
29 months ago
With skin in the game, Satsuma's partner offers buyout to get migraine spray to market
Fierce Biotech
Even as Satsuma Pharmaceuticals searched for a savior after a series of late-stage trial failures put its future in doubt, the U.S. biotech...
12 months ago